The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

VIDEO | Highly Sensitive and Specific Multiplexed Detection of Actionable Variants in EGFR, KRAS, BRAF, and ESR1 using ddPLEX Chemistry and the QX600 Droplet Digital PCR System

December 17, 2025

Click above to watch


On 30 October 2025, the EACR hosted a webinar in collaboration with Bio-Rad, one of our valued EACR Industry Partners. In this webinar, Leisa Jackson, lead R&D scientist at Biodesix, discussed her recent development work with two new assay formats that provide coverage of 11 variants commonly found in endocrine therapy-resistant HR+, HER2- metastatic breast cancer patients.

Thanks to Leisa and Bio-Rad, we are able to provide free on-demand access to the webinar recording, which can be found above.


Talk abstract

The Bio-Rad QX600 System is a next-generation droplet digital PCR platform designed for advanced target multiplexing. In this webinar, we report on our early access evaluation of the ddPLEX EGFR, KRAS, BRAF Multiplex Assay, which can simultaneously detect up to 37 key NSCLC variants in a single well using the QX600 System. We assessed assay performance in our CAP/CLIA accredited, ISO certified, and NYS CLEP approved clinical laboratory using remnant, de-identified cfDNA specimens from NSCLC donors.

This presentation also showcased Biodesix’s development work with the recently available ddPLEX ESR1 Mutation Detection Kit and ESR1 extended variant (EXV) Screening Assay. Together, the two assay formats provide coverage of 11 variants commonly found in endocrine therapy-resistant HR+, HER2- metastatic breast cancer patients. We observed detection at as low as 0.025% variant allele frequency in a plasma background. This level of sensitivity will be required for the early detection of acquired resistance to aromatase inhibitors in cell-free DNA.


Speaker

Leisa Jackson, Lead R&D scientist, Biodesix, Inc.

Leisa Jackson is a lead R&D scientist at Biodesix, Inc., in Louisville, Colorado. She has over 20 years of experience in molecular biology research, with a focus on translational science applications, including 10 years developing ddPCR and NGS assays for oncology diagnostic tests for both RUO and IVD applications. She earned her Bachelor of Science degree in Biological Science from Florida State University and has contributed to research in academic (FSU, Duke University, CU Boulder), clinical (National Jewish Health), and industry (Biodesix, Inc. and Invitae Corp.) settings.


Want more videos?

EACR members get exclusive access to a library of on-demand videos, from talks delivered at previous virtual conferences to webinars with leading authors and industry experts. Explore EACR membership today.

Tags: industryIndustry PartnersvideoWebinar

Related Posts

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms

October 1, 2026

Click above to watch On 29 September 2026, the EACR hosted a webinar in collaboration with Roche, one of our valued EACR Industry Partners. Antibody-Drug Conjugates...

From T-cell repertoires to biological insight: exploring antigen specificity in cancer immunology

From T-cell repertoires to biological insight: exploring antigen specificity in cancer immunology

September 16, 2026

Advances in next-generation sequencing (NGS) have transformed cancer immunology research. Today, researchers can profile T-cell receptor (TCR) repertoires in unprecedented detail, revealing how immune cell populations...

Highlights in Cancer Research: September 2026

Highlights in Cancer Research: September 2026

September 9, 2026

The EACR's 'Highlights in Cancer Research' is a regular summary of the most interesting and impactful recent papers in cancer research, curated by the Board of...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

Advertisement Advertisement Advertisement
ADVERTISEMENT

RECENT POSTS

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms
News

VIDEO | The Evolving ADC Landscape: From Monotherapies to Rational Combinations and Next-Generation Platforms

October 1, 2026
“An exchange that has had a lasting impact on my research, my laboratory and my development as a cancer researcher”:  Peijin Jiang’s Travel Fellowship
Community

“An exchange that has had a lasting impact on my research, my laboratory and my development as a cancer researcher”: Peijin Jiang’s Travel Fellowship

September 23, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR